COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial

Chiara Agrati; Serena Di Cosimo; Daniela Fenoglio; Giovanni Apolone; Fabio Ciceri; Gennaro Ciliberto; Fausto Baldanti; Massimo Costantini; Diana Giannarelli; Giuseppe Ippolito; Franco Locatelli; Alberto Mantovani; Aldo Morrone; Fabrizio Tagliavini; Antonio Uccelli; Pier Luigi Zinzani; Nicola Silvestris; Maria Rescigno

doi:10.3389/fimmu.2021.704110

COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial

Chiara Agrati, Serena Di Cosimo, Daniela Fenoglio, Giovanni Apolone, Fabio Ciceri, Gennaro Ciliberto, Fausto Baldanti, Massimo Costantini, Diana Giannarelli, Giuseppe Ippolito, Franco Locatelli, Alberto Mantovani, Aldo Morrone, Fabrizio Tagliavini, Antonio Uccelli, Pier Luigi Zinzani, Nicola Silvestris, Maria Rescigno

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Abstract

Patients diagnosed with malignancy, neurological and immunological disorders, i.e., fragile patients, have been excluded from COVID-19 vaccine trials. However, this population may present immune response abnormalities, and relative reduced vaccine responsiveness. Here we review the limited current evidence on the immune responses to vaccination of patients with different underlying diseases. To address open questions we present the VAX4FRAIL study aimed at assessing immune responses to vaccination in a large transdisease cohort of patients with cancer, neurological and rheumatological diseases.

Lingua originale	English
pagine (da-a)	1-8
Numero di pagine	8
Rivista	Frontiers in Immunology
Volume	12
DOI	https://doi.org/10.3389/fimmu.2021.704110
Stato di pubblicazione	Pubblicato - 2021

Keywords

cancer
COVID-19
vaccine
myasthenia
SARS-CoV-2
immunocompromised

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.3389/fimmu.2021.704110

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Agrati, C., Di Cosimo, S., Fenoglio, D., Apolone, G., Ciceri, F., Ciliberto, G., Baldanti, F., Costantini, M., Giannarelli, D., Ippolito, G., Locatelli, F., Mantovani, A., Morrone, A., Tagliavini, F., Uccelli, A., Zinzani, P. L., Silvestris, N., & Rescigno, M. (2021). COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial. Frontiers in Immunology, 12, 1-8. https://doi.org/10.3389/fimmu.2021.704110

@article{cf0f220957e24257bfe6b15569e762b1,

title = "COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial",

abstract = "Patients diagnosed with malignancy, neurological and immunological disorders, i.e., fragile patients, have been excluded from COVID-19 vaccine trials. However, this population may present immune response abnormalities, and relative reduced vaccine responsiveness. Here we review the limited current evidence on the immune responses to vaccination of patients with different underlying diseases. To address open questions we present the VAX4FRAIL study aimed at assessing immune responses to vaccination in a large transdisease cohort of patients with cancer, neurological and rheumatological diseases.",

keywords = "cancer, COVID-19, vaccine, myasthenia, SARS-CoV-2, immunocompromised, cancer, COVID-19, vaccine, myasthenia, SARS-CoV-2, immunocompromised",

author = "Chiara Agrati and {Di Cosimo}, Serena and Daniela Fenoglio and Giovanni Apolone and Fabio Ciceri and Gennaro Ciliberto and Fausto Baldanti and Massimo Costantini and Diana Giannarelli and Giuseppe Ippolito and Franco Locatelli and Alberto Mantovani and Aldo Morrone and Fabrizio Tagliavini and Antonio Uccelli and Zinzani, {Pier Luigi} and Nicola Silvestris and Maria Rescigno",

year = "2021",

doi = "10.3389/fimmu.2021.704110",

language = "English",

volume = "12",

pages = "1--8",

journal = "Frontiers in Immunology",

issn = "1664-3224",

publisher = "Frontiers Media SA",

}

Agrati, C, Di Cosimo, S, Fenoglio, D, Apolone, G, Ciceri, F, Ciliberto, G, Baldanti, F, Costantini, M, Giannarelli, D, Ippolito, G, Locatelli, F, Mantovani, A, Morrone, A, Tagliavini, F, Uccelli, A, Zinzani, PL, Silvestris, N & Rescigno, M 2021, 'COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial', Frontiers in Immunology, vol. 12, pagg. 1-8. https://doi.org/10.3389/fimmu.2021.704110

TY - JOUR

T1 - COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial

AU - Agrati, Chiara

AU - Di Cosimo, Serena

AU - Fenoglio, Daniela

AU - Apolone, Giovanni

AU - Ciceri, Fabio

AU - Ciliberto, Gennaro

AU - Baldanti, Fausto

AU - Costantini, Massimo

AU - Giannarelli, Diana

AU - Ippolito, Giuseppe

AU - Locatelli, Franco

AU - Mantovani, Alberto

AU - Morrone, Aldo

AU - Tagliavini, Fabrizio

AU - Uccelli, Antonio

AU - Zinzani, Pier Luigi

AU - Silvestris, Nicola

AU - Rescigno, Maria

PY - 2021

Y1 - 2021

N2 - Patients diagnosed with malignancy, neurological and immunological disorders, i.e., fragile patients, have been excluded from COVID-19 vaccine trials. However, this population may present immune response abnormalities, and relative reduced vaccine responsiveness. Here we review the limited current evidence on the immune responses to vaccination of patients with different underlying diseases. To address open questions we present the VAX4FRAIL study aimed at assessing immune responses to vaccination in a large transdisease cohort of patients with cancer, neurological and rheumatological diseases.

AB - Patients diagnosed with malignancy, neurological and immunological disorders, i.e., fragile patients, have been excluded from COVID-19 vaccine trials. However, this population may present immune response abnormalities, and relative reduced vaccine responsiveness. Here we review the limited current evidence on the immune responses to vaccination of patients with different underlying diseases. To address open questions we present the VAX4FRAIL study aimed at assessing immune responses to vaccination in a large transdisease cohort of patients with cancer, neurological and rheumatological diseases.

KW - cancer

KW - COVID-19

KW - vaccine

KW - myasthenia

KW - SARS-CoV-2

KW - immunocompromised

KW - cancer

KW - COVID-19

KW - vaccine

KW - myasthenia

KW - SARS-CoV-2

KW - immunocompromised

UR - http://hdl.handle.net/10807/228529

U2 - 10.3389/fimmu.2021.704110

DO - 10.3389/fimmu.2021.704110

M3 - Article

SN - 1664-3224

VL - 12

SP - 1

EP - 8

JO - Frontiers in Immunology

JF - Frontiers in Immunology

ER -

COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo